1. |
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90.
|
2. |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108.
|
3. |
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010, 127(12): 2893-2917.
|
4. |
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology, 2011, 53(3): 1020-1022.
|
5. |
Ming L, Thorgeirsson SS, Gail MH, et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology, 2002, 36(5): 1214-1220.
|
6. |
Sohn W, Paik YH, Lee MW, et al. Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation. Scand J Gastroenterol, 2014, 49(3): 373-380.
|
7. |
Sasaki K, Shindoh J, Nishioka Y, et al. Impact of viral etiology on postoperative De Novo recurrence after hepatectomy for hepatocellular carcinoma in cirrhotic patients. J Gastrointest Surg, 2017, 21(3): 487-495.
|
8. |
Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol, 2006, 45(4): 529-538.
|
9. |
Yang T, Lu JH, Zhai J, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol, 2012, 38(8): 683-691.
|
10. |
Yu SJ, Kim YJ. Hepatitis B viral load affects prognosis of hepatocellular carcinoma. World J Gastroenterol, 2014, 20(34): 12039-12044.
|
11. |
Meng W, Bai B, Bai Z, et al. The immunosuppression role of alpha-fetoprotein in human hepatocellular carcinoma. Discov Med, 2016, 21(118): 489-494.
|
12. |
Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2015, 16(13): 1344-1354.
|
13. |
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379(9822): 1245-1255.
|
14. |
Goldstein AL, Guha A, Zatz MM, et al. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci USA, 1972, 69(7): 1800-1803.
|
15. |
Fan YZ, Chang H, Yu Y, et al. Thymosin alpha1 suppresses proliferation and induces apoptosis in human leukemia cell lines. Peptides, 2006, 27(9): 2165-2173.
|
16. |
Moretti S, Oikonomou V, Garaci E, et al. Thymosin alpha 1: burying secrets in the thymus. Expert Opin Biol Ther, 2015, 15(1): S51-S58.
|
17. |
Serafino A, Pierimarchi P, Pica F, et al. Thymosin alpha1 as a stimulatory agent of innate cell-mediated immune response. Ann N Y Acad Sci, 2012, 1270: 13-20.
|
18. |
Gish RG, Gordon SC, Nelson D, et al. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int, 2009, 3(3): 480-489.
|
19. |
Jeng WJ, Lin CC, Chen WT, et al. Adjuvant therapy for hepatocellular carcinoma after curative treatment. Dig Dis, 2014, 32(6): 747-754.
|
20. |
Kim BK, Jy P, Kim DY, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int, 2008, 28(3): 393-401.
|
21. |
Cheng SQ, Wu MC, Chen H, et al. Antiviral therapy using lamivudine and thymosin α1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepato-gastroenterology, 2006, 53(68): 249-252.
|
22. |
He C, Peng W, Li C, et al. Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection. Medicine, 2017, 96(16): e6606.
|
23. |
Watanabe H, Okada M, Kaji Y, et al. New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1). Gan To Kagaku Ryoho, 2009, 36(13): 2495-2501.
|
24. |
National Cancer Institute. Common terminology criteria for adverse events v. 3.0 and v. 4.0 (CTCAE). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
|
25. |
Sonnenberg F, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making, 1993, 13(4): 322-338.
|
26. |
Purmonen T, Martikainen JA, Soini EJ, et al. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther, 2008, 30(2): 382-392.
|
27. |
《中国药物经济学评价指南》课题组, 刘国恩, 胡善联, 等. 中国药物经济学评价指南 (2011 版). 中国药物经济学, 2011(3): 6-48.
|
28. |
Cucchetti A, Piscaglia F, Cescon M, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol, 2013, 59(2): 300-307.
|
29. |
Suh CH, Kim KW, Park SH, et al. Performing gadoxetic acid-enhanced MRI after CT for guiding curative treatment of early-stage hepatocellular carcinoma: a cost-effectiveness analysis. AJR Am J Roentgenol, 2018, 210(2): W63-W69.
|
30. |
Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ, 2000, 9(3): 235-251.
|
31. |
Tangka FK, Trogdon JG, Richardson LC, et al. Cancer treatment cost in the United States has the burden shifted over time?. Cancer, 2010, 116(14): 3477-3484.
|
32. |
Zhang P, Yang Y, Wen F, et al. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol, 2016, 31(12): 1978-1985.
|
33. |
Ko CJ, Chien SY, Chou CT, et al. Factors affecting prognosis of small hepatocellular carcinoma in Taiwanese patients following hepatic resection. Can J Gastroenterol, 2011, 25(9): 485-491.
|
34. |
Hosaka T, Ikeda K, Kobayashi M, et al. Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma. Liver Int, 2009, 29(5): 736-742.
|
35. |
Hung H. Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets, 2005, 5(2): 131-138.
|
36. |
宋继勇, 杜国盛, 朱志东, 等. 胸腺法新在肿瘤患者肝移植术后应用的安全性研究. 中华损伤与修复杂志: 电子版, 2014, 9(2): 166-168.
|
37. |
邱济海, 杨亦德. 胸腺法新联合恩替卡韦治疗慢性乙型肝炎效果观察. 中国乡村医药, 2018, 25(2): 24-25.
|
38. |
李涛, 李政文, 文华长. 高剂量胸腺五肽在原发性肝癌栓塞治疗中的应用和安全性研究. 中华肿瘤杂志, 2007, 29(12): 941-942.
|